What is the recommended intravenous clarithromycin dosing for adults and children, including adjustments for renal impairment?

Clarithromycin IV Dosing

Clarithromycin is not available in an intravenous formulation in the United States—only oral formulations (tablets and suspension) are FDA-approved. 1

Critical Clarification

The FDA-approved clarithromycin formulations are:

• Oral tablets: 250 mg, 500 mg
• Oral suspension: 125 mg/5 mL, 250 mg/5 mL

There is no FDA-approved intravenous clarithromycin product available in the U.S. While IV clarithromycin exists in some other countries, it is not licensed for use in the United States.

Standard Oral Dosing (FDA-Approved)

Adults

• Standard infections: 250-500 mg orally every 12 hours for 7-14 days (depending on indication) 1
• Mycobacterial infections: 500 mg orally twice daily 1

Children

• Standard dose: 15 mg/kg/day divided every 12 hours (maximum 1 g/day) 2, 1
• Alternative calculation: 7.5 mg/kg every 12 hours 1
• Mycobacterial infections: 7.5 mg/kg twice daily (maximum 500 mg per dose) 1

Contraindication: Not recommended for infants <1 month due to unknown association with infantile hypertrophic pyloric stenosis 2

Renal Impairment Adjustments

Adults

• CrCl ≥30 mL/min: No adjustment needed 1
• CrCl <30 mL/min: Reduce dose by 50% 3, 1

Special Considerations with Antiretrovirals

When used with atazanavir or ritonavir:

• CrCl 30-60 mL/min: Reduce clarithromycin dose by 50% 1
• CrCl <30 mL/min: Reduce clarithromycin dose by 75% 1

Hepatic Impairment

• No dose adjustment required if renal function is normal 1

Alternative IV Macrolides for Critical Illness

Since IV clarithromycin is unavailable in the U.S., consider these alternatives when parenteral therapy is required:

For Atypical Pneumonia Coverage

• Azithromycin IV: 10 mg/kg on days 1-2 (pediatrics), then transition to oral 4
• Erythromycin lactobionate IV: 20 mg/kg/day every 6 hours (pediatrics) 4

For Community-Acquired Pneumonia

Guidelines recommend azithromycin IV as the preferred parenteral macrolide, with transition to oral therapy as soon as clinically appropriate 4

Important Drug Interactions

Clarithromycin is a potent CYP3A4 inhibitor and has significant interactions with:

• Contraindicated: astemizole, cisapride, pimozide, terfenadine 2
• Requires monitoring: carbamazepine, cyclosporin, digoxin, theophylline, warfarin 5
• Rifamycins significantly decrease clarithromycin levels 5

Clinical Pharmacokinetics

• Oral bioavailability: 52-55% 5
• Half-life: 3.3-4.9 hours 5
• Tissue penetration: Extensive into respiratory tissues, achieving concentrations higher than plasma 5, 6
• Active metabolite: 14-hydroxyclarithromycin contributes to activity, particularly against H. influenzae 5, 6